Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University of Duesseldorf, Duesseldorf, Germany.
Leuk Res. 2012 Dec;36(12):1463-9. doi: 10.1016/j.leukres.2012.08.005. Epub 2012 Sep 12.
Prognostic scoring systems in myelodysplastic syndromes are useful tools in order to get in idea on the expected course of the disease and offer patients a risk adapted treatment. Several good scores have been developed, the international prognostic scoring system (IPSS) being the gold standard for 15 years, now validated and refined. As more and more patients receive therapy and drugs are approved, the major goal for future projects must be the identification of predictive parameters and scoring systems in order to predict the response and outcome after specific treatments.
预后评分系统在骨髓增生异常综合征中是非常有用的工具,可以了解疾病的预期进程,并为患者提供风险适应性治疗。已经开发了几种较好的评分系统,国际预后评分系统(IPSS)作为 15 年来的金标准,现在已经得到验证和完善。随着越来越多的患者接受治疗和药物的批准,未来项目的主要目标必须是确定预测参数和评分系统,以预测特定治疗后的反应和结果。